HDAC Inhibitors – A Pipeline Analysis Report 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
HDAC INHIBITORS PIPELINE ANALYSIS
• Histone Deacetylase (HDAC), the superfamily group of enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone.
• They are responsible for gene expression and regulation, which is responsible for cellular functioning. It also helps in the wrapping of histone over the Deoxyribonucleic acid (DNA). It has an extended history of use in psychiatry and neurology as anti-epileptics and mood stabilizers.
• More recently they are being explored as possible treatments for cancer, parasitic and inflammatory diseases. Thus, the development of HDAC inhibitors, targeted drug molecules inhibit the activity of HDACs, gains a lot of interest from academic researchers and biopharmaceutical firms.
• A problem arising with the already available HDAC inhibitors is that they target multiple deacetylases and have limited specificity. Designing isoform-selective inhibitors have proven troublesome due to similarities in the structure and chemistry of active sites of HDAC.
• Globally, an increase in the number of cancer patients across the globe and the need to improve the effectiveness of new therapies are the prime growth drivers of HDAC inhibitors market. However, many challenges stick around due to the complexity involved in the lysine posttranslational modifications, non-epigenetic cellular signaling cascades, and epigenetic transcription regulation.
• With the availability of a limited number of marketed HDAC inhibitors, pharmaceutical companies are now heavily investing in research and development activities and preclinical activities of HDAC inhibitors for different applications.
• There are some of the commercialized HDAC inhibitors, most of them are primarily targeting hematological malignancies. Approval of the first HDAC inhibitor, Zolinza (vorinostat) developed by Merck & Co., Inc., for CTCL treatment gave the market an initial impulse.
• The instigation was carried on by the other molecules Istodax developed by Gloucester pharmaceuticals, Beleodaq by Spectrum Pharmaceuticals, Epidaza by Chipscreen Bioscience and Farydak by Novartis. Nearly 90 HDAC inhibitors are at present in various stages of development both clinically and preclinically, of which the clinical molecules account for over 30% of the pipeline molecules capture over 60% in the preclinical / discovery stage.
• Few of the key pipeline HDAC inhibitors include entinostat by Syndax Pharmaceuticals, pracinostat (SB939) by MEI Pharma, abexinostat by Celera Genomics Group, CHR-5154, CKD-581, RG2833, MPT0E028, and CS3158. These are analyzed based on the route of administration (ROA) and type of molecule.
• Histone Deacetylase (HDAC), the superfamily group of enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone.
• They are responsible for gene expression and regulation, which is responsible for cellular functioning. It also helps in the wrapping of histone over the Deoxyribonucleic acid (DNA). It has an extended history of use in psychiatry and neurology as anti-epileptics and mood stabilizers.
• More recently they are being explored as possible treatments for cancer, parasitic and inflammatory diseases. Thus, the development of HDAC inhibitors, targeted drug molecules inhibit the activity of HDACs, gains a lot of interest from academic researchers and biopharmaceutical firms.
• A problem arising with the already available HDAC inhibitors is that they target multiple deacetylases and have limited specificity. Designing isoform-selective inhibitors have proven troublesome due to similarities in the structure and chemistry of active sites of HDAC.
• Globally, an increase in the number of cancer patients across the globe and the need to improve the effectiveness of new therapies are the prime growth drivers of HDAC inhibitors market. However, many challenges stick around due to the complexity involved in the lysine posttranslational modifications, non-epigenetic cellular signaling cascades, and epigenetic transcription regulation.
• With the availability of a limited number of marketed HDAC inhibitors, pharmaceutical companies are now heavily investing in research and development activities and preclinical activities of HDAC inhibitors for different applications.
• There are some of the commercialized HDAC inhibitors, most of them are primarily targeting hematological malignancies. Approval of the first HDAC inhibitor, Zolinza (vorinostat) developed by Merck & Co., Inc., for CTCL treatment gave the market an initial impulse.
• The instigation was carried on by the other molecules Istodax developed by Gloucester pharmaceuticals, Beleodaq by Spectrum Pharmaceuticals, Epidaza by Chipscreen Bioscience and Farydak by Novartis. Nearly 90 HDAC inhibitors are at present in various stages of development both clinically and preclinically, of which the clinical molecules account for over 30% of the pipeline molecules capture over 60% in the preclinical / discovery stage.
• Few of the key pipeline HDAC inhibitors include entinostat by Syndax Pharmaceuticals, pracinostat (SB939) by MEI Pharma, abexinostat by Celera Genomics Group, CHR-5154, CKD-581, RG2833, MPT0E028, and CS3158. These are analyzed based on the route of administration (ROA) and type of molecule.
